You are here: Home » Markets » News
Business Standard

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Among sectoral indices, the Nifty Pharma index ended over 3 per cent higher led by rise in the shares of Sun Pharmaceutical Industries and Lupin.

Topics
Market Wrap  |  Nifty  |  Sensex

SI Reporter  |  New Delhi 

The benchmark indices ended higher on Tuesday, taking cues from their global peers and helped by pharmaceutical, information technology and financial stocks. The S&P BSE Sensex ended at 37,852, up 207 points while the broader Nifty50 index settled at 11,435, up 79 points. In key stocks, the market heavyweight Reliance Industries (RIL) rose 2 per cent to Rs 1,210.95 levels on the BSE. Sun Pharmaceutical Industries too surged around 7 per cent to end at Rs 601.65. Among sectoral indices, the Nifty Pharma index ended over 3 per cent higher led by rise in the ...

MONTHLY STAR

Business Standard Digital

Business Standard Digital Monthly Subscription
199.00  
subscribe
Complete access to the premium product
Convenient - Pay as you go
Pay using Amex/Master/VISA Credit Cards and VISA Debit Cards Only
Auto renewed (subject to your card issuer's permission)
Cancel any time in the future
Requires personal information

What you get?

ON BUSINESS STANDARD DIGITAL

  • Unlimited access to all the content on any device through browser or app.
  • Exclusive content, features, opinions and comment – hand-picked by our editors, just for you.
  • Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
  • Track the industry of your choice with a daily newsletter specific to that industry.
  • Stay on top of your investments. Track stock prices in your portfolio.
  • 18 years of archival data.

NOTE :

  • The product is a monthly auto renewal product.
  • Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
  • To cancel, communicate from your registered email id and send the email with the cancellation request to assist@bsmail.in. Include your contact number for speedy action. Requests mailed to any other ID will not be acknowledged or actioned upon.

SMART ANNUAL

Business Standard Digital
Subscribe Now and get 12 months Free

Business Standard Premium Digital - 12 Months + 12 Months Free
1799.00
subscribe
Subscribe for 12 months and get 12 months free.
Single Seamless Sign-up to Business Standard Digital
Convenient - Once a year payment
Pay using an instrument of your choice -all Credit and Debit Cards, Net Banking, Payment Wallets, and UPI
Exclusive Invite to select Business Standard events

What you get

ON BUSINESS STANDARD DIGITAL

  • Unlimited access to all content on any device through browser or app.
  • Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
  • Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
  • Track the industry of your choice with a daily newsletter specific to that industry.
  • Stay on top of your investments. Track stock prices in your portfolio.

NOTE :

  • The monthly duration product is an auto renewal based product. Once subscribed, subject to your card issuer's permission we will charge your card/ payment instrument each month automatically and renew your subscription.
  • In the Annual duration product we offer both an auto renewal based product and a non auto renewal based product.
  • We do not Refund.
  • No Questions asked Cancellation Policy.
  • You can cancel future renewals anytime including immediately upon subscribing but 48 hours before your next renewal date.
  • Subject to the above, self cancel by visiting the "Manage My Account“ section after signing in OR Send an email request to assist@bsmail.in from your registered email address and by quoting your mobile number.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Nifty Pharma index ends 3.21% higher. Top gainers: COMPANY LATEST PREV CLOSE GAIN() GAIN(%) SUN PHARMA.INDS. 601.80 563.90 37.90 6.72 BIOCON 589.40 571.70 17.70 3.10 DIVI'S LAB. 1154.55 1120.20 34.35 3.07 LUPIN 836.75 811.95 24.80 3.05 CIPLA 642.75 628.30 14.45 2.30

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Nifty sectoral gainers and losers

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

BSE Sensex: Sun Pharma, YES Bank, RIL among top gainers of the day

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Market at close The S&P BSE Sensex ended at 37,852, up 207 points while the broader Nifty50 index settled at 11,435, up 79 points.

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

External factors, selective intervention by RBI led to rupee's fall: Garg The government on Tuesday blamed "external factors" for the rupee's fall to an all-time low against the US dollar and said there is nothing to worry. Economic Affairs Secretary Subhash Chander Garg said external factors may ease going forward. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Sun Pharma rallies 7% as Q1 profit beats Street estimates Shares of Sun Pharmaceutical Industries have rallied 7% to Rs 600 per share on the BSE after the pharmaceutical company reported a better-than-expected consolidated net profit at Rs 9.83 billion in June quarter (Q1FY19). The company had posted a loss of Rs 4.25 billion in the same quarter year ago. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

MCX to launch rubber futures on Aug 16 Leading commodity bourse MCX today announced launching of the rubber futures from August 16 to provide hedging to the entire value chain in the rubber industry. The MCX said it will offer four futures contracts in rubber with each ending September, October, November and December, respectively, an official statement said. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Sebi's consent route to ease pending case load yields success in FY18   Markets regulator Securities and Exchange Board of India (Sebi) settled double the number of cases through the so-called consent mechanism in 2017-18, compared to the previous fiscal. According to data, Sebi resolved 200 cases through the consent route last fiscal as against 103 in 2016-17.   The amount earned by Sebi as settlement fees also saw a more than two-fold increase to Rs 300 million in FY18, compared to Rs 135 million in FY17. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

STOCK ALERT Cadila Healthcare nears 52-week low post June quarter results   Shares of Cadila Healthcare have slipped 5% to Rs 336 per share, extending their 6% decline on Monday on the BSE, after the company reported a lower-than-expected 30% year on year (YoY) growth in net sales at Rs 28.94 billion in the June quarter (Q1FY19) due to lower US sales.   The company’s net profit grew by 233% YoY to Rs 4.60 billion in Q1FY19 due to other income of Rs 1.01 billion. READ MORE

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Market Check INDEX LATEST PREVIOUS CHANGE CHANGE(%) NIFTY 50 11439.80 11355.75 84.05 0.74 NIFTY 500 9718.75 9656.50 62.25 0.64 NIFTY MIDCAP 100 19114.50 19012.40 102.10 0.54 NIFTY SMALL 100 7473.65 7463.65 10.00 0.13 INDIA VIX 13.23 13.40 -0.17 -1.27 > More on NSE Indices

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

COMMENT Aditi Nayar, Principal economist, ICRA on rupee, inflation As expected, a favourable base effect for primary food items and minerals, dampened the WPI inflation to 5.1% in July 2018 from 5.8% in June 2018, mirroring the extent of the correction displayed by the CPI inflation print. Contagion related to the crisis in Turkey has seeped into other emerging market currencies, causing the INR to depreciate as well. Factors such as broader emerging market currency movement, dollar strength, and the trend in crude oil prices will drive the outlook for the INR in the immediate term, which will have an impact on the landed cost of imports as well as various commodity prices, thereby transmitting into the WPI inflation. Given the prevailing risk aversion in the global markets, the rupee is expected to remain volatile going ahead, and average 68.5/USD in FY2019

First Published: Tue, August 14 2018. 08:15 IST
RECOMMENDED FOR YOU

MARKET WRAP: Sensex ends 207 pts up led by RIL, Sun Pharma; Rupee hits 70/$

Among sectoral indices, the Nifty Pharma index ended over 3 per cent higher led by rise in the shares of Sun Pharmaceutical Industries and Lupin.

The benchmark indices ended higher on Tuesday, taking cues from their global peers and helped by pharmaceutical, information technology and financial stocks. The S&P BSE Sensex ended at 37,852, up 207 points while the broader Nifty50 index settled at 11,435, up 79 points. In key stocks, the market heavyweight Reliance Industries (RIL) rose 2 per cent to Rs 1,210.95 levels on the BSE. Sun Pharmaceutical Industries too surged around 7 per cent to end at Rs 601.65. Among sectoral indices, the Nifty Pharma index ended over 3 per cent higher led by rise in the ...

image
Business Standard
177 22
.